KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to $86.6 million.

  • Royalty Pharma's Other Non-Current Assets rose 10235.34% to $86.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.6 million, marking a year-over-year increase of 10235.34%. This contributed to the annual value of $33.5 million for FY2024, which is 41416.74% up from last year.
  • Royalty Pharma's Other Non-Current Assets amounted to $86.6 million in Q3 2025, which was up 10235.34% from $85.5 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Other Non-Current Assets peaked at $86.6 million during Q3 2025, and registered a low of $3.9 million during Q1 2022.
  • Its 5-year average for Other Non-Current Assets is $27.2 million, with a median of $28.0 million in 2023.
  • Per our database at Business Quant, Royalty Pharma's Other Non-Current Assets plummeted by 8398.86% in 2024 and then soared by 71789.22% in 2025.
  • Over the past 5 years, Royalty Pharma's Other Non-Current Assets (Quarter) stood at $4.1 million in 2021, then skyrocketed by 614.81% to $29.6 million in 2022, then tumbled by 77.99% to $6.5 million in 2023, then soared by 414.17% to $33.5 million in 2024, then surged by 158.2% to $86.6 million in 2025.
  • Its last three reported values are $86.6 million in Q3 2025, $85.5 million for Q2 2025, and $36.7 million during Q1 2025.